Skip to main content
. Author manuscript; available in PMC: 2023 Oct 10.
Published in final edited form as: Cancer Cell. 2022 Sep 29;40(10):1161–1172.e5. doi: 10.1016/j.ccell.2022.08.022

Figure 2: See also Figure S5 and Tables S3-S4. Differential TMB estimates across continental ancestral populations in the DFCI cohorts prior and after calibration and effects of TMB calibration on clinical outcomes.

Figure 2:

A. Distribution of uncalibrated TMB estimates for each of 7 cancer types shown by genetic ancestry. A two-sided binomial test was used to establish P values (* <0.05, ** <0.01, *** <0.001, **** <0.0001). Data are represented as boxplots. The horizontal lines reflect the median, the lower and upper whiskers indicate 1.5 x the interquartile ranges. Circles are outliers. B. Distribution of calibrated TMB estimates for each of 7 cancer types shown by genetic ancestry. A two-sided binomial test was used to establish P values (* <0.05, ** <0.01, *** <0.001, **** <0.0001). Data are represented as boxplots. The horizontal lines reflect the median, the lower and upper whiskers indicate 1.5 x the interquartile ranges. Circles are outliers. C. 10x10 dot plot showing TMB misclassification rates for TMB-high tumors in each ancestral population in the entire DFCI cohort (n=2800 TMB-high patients). D. Impact of TMB calibration on overall survival in ICI-treated patients at DFCI (n=1840 patients). Patients were stratified into: (a) true TMB-low (raw TMB<10; calibrated TMB<10), true TMB-high (raw TMB≥10; calibrated TMB ≥10), and false TMB-high (raw TMB ≥10, calibrated TMB<10). CRC: colorectal cancer, EGC: esophagogastric cancer (EGC), HNSCC: head and neck squamous cell carcinoma, melanoma, NSCLC: non-small cell lung cancer, UC: urothelial carcinoma, RCC: renal cell carcinoma. See also Figure S5 and Tables S3-S4.